What is the treatment for a UTI (Urinary Tract Infection) associated with schistosomiasis, specifically Schistosoma haematobium?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of UTI Associated with Schistosoma haematobium

Praziquantel at a dose of 40 mg/kg as a single dose is the recommended treatment for urinary tract infection associated with Schistosoma haematobium. 1

Diagnosis and Clinical Presentation

Schistosoma haematobium infection typically presents with:

  • Urinary symptoms (dysuria, frequency, urgency)
  • Hematuria (microscopic or macroscopic)
  • Proteinuria
  • Potential complications including bladder stones, obstructive uropathy, and bacterial superinfection

The diagnosis should be confirmed through:

  • Microscopy of terminal urine samples (preferably collected at midday when egg shedding peaks)
  • Serology testing
  • Urine dipstick for hematuria and proteinuria (though this has low sensitivity)

Treatment Algorithm

First-Line Treatment

  • Praziquantel 40 mg/kg as a single oral dose 1
  • For travelers or those with suspected high-intensity infections, some experts suggest repeating the treatment after 6-8 weeks to ensure complete clearance 1

Special Considerations

  • If neurological symptoms are present (suggesting neuroschistosomiasis), corticosteroids should be initiated before antischistosomal therapy to avoid neurological complications 1
  • For patients with confirmed bacterial UTI superinfection, appropriate antibiotics should be administered in addition to praziquantel

Treatment Failures

If treatment failure occurs (persistent eggs in urine after 4-6 weeks):

  • Consider repeating praziquantel at 60 mg/kg in two divided doses 1
  • Some treatment failures have been reported in travelers with S. haematobium, suggesting possible tolerance to standard doses in some strains 2

Monitoring and Follow-up

  • Repeat urine examination at 4-6 weeks post-treatment
  • Serology is not useful for monitoring treatment success as it may remain positive for years 1
  • Monitor for resolution of hematuria and proteinuria
  • Consider ultrasound to evaluate for complications in cases of heavy infection

Efficacy and Safety

  • Praziquantel has demonstrated cure rates of >90% for S. haematobium at the standard dose 3, 4
  • The drug is generally well-tolerated with mostly mild to moderate adverse effects including:
    • Abdominal pain (most common)
    • Nausea
    • Dizziness
    • Headache

Important Caveats

  • Eggs and immature schistosomulae are relatively resistant to treatment, which is why repeat treatment after 6-8 weeks may be necessary 1
  • Serology may remain positive for many years after successful treatment, so it cannot be used to assess cure 1
  • S. haematobium infection has been linked to squamous cell carcinoma of the bladder, so patients with heavy or chronic infections warrant further urological investigation 1
  • Swimmers' itch (cercarial dermatitis) is a separate entity caused by non-human schistosome species and resolves spontaneously without specific treatment 1

Prevention

For prevention of reinfection or new infections:

  • Avoid contact with freshwater in endemic areas
  • If exposure occurs, vigorous towel drying may help prevent cercarial penetration
  • Treat all infected individuals in endemic communities to reduce transmission

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Drugs for treating urinary schistosomiasis.

The Cochrane database of systematic reviews, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.